{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:01:35Z","timestamp":1790733695749,"version":"4.1.0"},"reference-count":124,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T00:00:00Z","timestamp":1645228800000},"content-version":"am","delay-in-days":414,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005865","name":"Mochida Memorial Foundation for Medical and Pharmaceutical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004330","name":"Smoking Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bbrc.2020.10.094","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T15:36:35Z","timestamp":1605886595000},"page":"137-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in\u00a0vitro approaches"],"prefix":"10.1016","volume":"538","author":[{"given":"Koichi","family":"Watashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.10.094_bib1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2020.10.094_bib2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A\u00a0pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib3","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A\u00a0novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2020.10.094_bib4","first-page":"172","article-title":"The cost of new drug discovery and development","volume":"4","author":"Dickson","year":"2004","journal-title":"Discov. Med."},{"key":"10.1016\/j.bbrc.2020.10.094_bib5","doi-asserted-by":"crossref","first-page":"104269","DOI":"10.1016\/j.bioorg.2020.104269","article-title":"Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19","volume":"104","author":"Faheem","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrc.2020.10.094_bib6","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","article-title":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbrc.2020.10.094_bib7","first-page":"341","article-title":"Whole genome analysis and targeted drug discovery using computational methods and high throughput screening tools for emerged novel coronavirus (2019-nCoV)","volume":"3","author":"Manikyam","year":"2020","journal-title":"J.\u00a0Pharm. Drug. Res."},{"key":"10.1016\/j.bbrc.2020.10.094_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib9","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1038\/s41467-020-16954-7","article-title":"Structural plasticity of SARS-CoV-2 3CL M(pro) active site cavity revealed by room temperature X-ray crystallography","volume":"11","author":"Kneller","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.10.094_bib10","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1038\/s41467-020-18096-2","article-title":"Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.10.094_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.094_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1764392","article-title":"Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2","author":"Al-Khafaji","year":"2020","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2020.10.094_bib13","doi-asserted-by":"crossref","first-page":"118080","DOI":"10.1016\/j.lfs.2020.118080","article-title":"Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations","volume":"257","author":"Bharadwaj","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2020.10.094_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25112529","article-title":"Silico evaluation of the effectivity of approved protease inhibitors against the main protease of the novel SARS-CoV-2 virus","volume":"25","author":"Eleftheriou","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2020.10.094_bib15","doi-asserted-by":"crossref","first-page":"101646","DOI":"10.1016\/j.tmaid.2020.101646","article-title":"A\u00a0search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease","volume":"35","author":"Hall","year":"2020","journal-title":"Trav. Med. Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.094_bib16","doi-asserted-by":"crossref","first-page":"118205","DOI":"10.1016\/j.lfs.2020.118205","article-title":"Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: virtual screening, molecular docking, and molecular dynamics simulation study","volume":"258","author":"Hosseini","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2020.10.094_bib17","first-page":"1","article-title":"In-silico drug repurposing and molecular dynamics puzzled out potential SARS-CoV-2 main protease inhibitors","author":"Ibrahim","year":"2020","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2020.10.094_bib18","doi-asserted-by":"crossref","first-page":"117627","DOI":"10.1016\/j.lfs.2020.117627","article-title":"Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease","volume":"251","author":"Kandeel","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.bbrc.2020.10.094_bib19","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jiph.2020.06.016","article-title":"Silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing","volume":"13","author":"Kumar","year":"2020","journal-title":"J.\u00a0Infect. Public Health"},{"key":"10.1016\/j.bbrc.2020.10.094_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07391102.2020.1764393","article-title":"FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication","author":"Lobo-Galo","year":"2020","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2020.10.094_bib21","first-page":"1","article-title":"Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an in silico based approach","author":"Mahanta","year":"2020","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2020.10.094_bib22","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20201256","article-title":"Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy","volume":"40","author":"Shamsi","year":"2020","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.bbrc.2020.10.094_bib23","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1021\/acs.jcim.0c00179","article-title":"Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study","volume":"60","author":"Wang","year":"2020","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.bbrc.2020.10.094_bib24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12539-020-00376-6","article-title":"Deep learning based drug screening for novel coronavirus 2019-nCov","volume":"12","author":"Zhang","year":"2020","journal-title":"Interdis. Sci."},{"key":"10.1016\/j.bbrc.2020.10.094_bib25","article-title":"Crystal structure of SARS-CoV-2 papain-like protease","author":"Gao","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbrc.2020.10.094_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","author":"Shin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib27","article-title":"Silico drug repurposing for COVID-19: targeting SARS-CoV-2 proteins through docking and consensus ranking","author":"Cavasotto","year":"2020","journal-title":"Mol. Inform."},{"key":"10.1016\/j.bbrc.2020.10.094_bib28","first-page":"1","article-title":"Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease","author":"Kandeel","year":"2020","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2020.10.094_bib29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.094_bib30","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","author":"Hillen","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cell.2020.05.034","article-title":"Structural basis for RNA replication by the SARS-CoV-2 polymerase","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib32","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.094_bib33","doi-asserted-by":"crossref","first-page":"107774","DOI":"10.1016\/j.celrep.2020.107774","article-title":"Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2","volume":"31","author":"Peng","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2020.10.094_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e04502","article-title":"SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - a drug repurposing study","volume":"6","author":"Ahmad","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrc.2020.10.094_bib35","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1038\/s41598-020-66440-9","article-title":"Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic","volume":"10","author":"Jacome","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2020.10.094_bib36","first-page":"1","article-title":"Targeting SARS-CoV-2 Nsp12\/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach","author":"Mutlu","year":"2020","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2020.10.094_bib37","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1099\/jmm.0.001203","article-title":"Potential RNA-dependent RNA polymerase inhibitors as prospective therapeutics against SARS-CoV-2","volume":"69","author":"Pokhrel","year":"2020","journal-title":"J.\u00a0Med. Microbiol."},{"key":"10.1016\/j.bbrc.2020.10.094_bib38","first-page":"1","article-title":"A\u00a0computational approach to drug repurposing against SARS-CoV-2 RNA dependent RNA polymerase (RdRp)","author":"Ribaudo","year":"2020","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2020.10.094_bib39","article-title":"SARS-CoV-2 and SARS-CoV: virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12)","author":"Ruan","year":"2020","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.bbrc.2020.10.094_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib41","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.094_bib42","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib43","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib44","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib45","doi-asserted-by":"crossref","first-page":"7058","DOI":"10.1021\/acs.jpclett.0c02278","article-title":"Screening of therapeutic agents for COVID-19 using machine learning and ensemble docking studies","volume":"11","author":"Batra","year":"2020","journal-title":"J.\u00a0Phys. Chem. Lett."},{"key":"10.1016\/j.bbrc.2020.10.094_bib46","first-page":"663","volume":"vol. 9","author":"Br","year":"2020"},{"key":"10.1016\/j.bbrc.2020.10.094_bib47","first-page":"1","article-title":"Repurposing approved drugs as inhibitors of SARS-CoV-2 S-protein from molecular modeling and virtual screening","author":"de Oliveira","year":"2020","journal-title":"J.\u00a0Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrc.2020.10.094_bib48","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12860-020-00294-x","article-title":"Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity","volume":"21","author":"Drew","year":"2020","journal-title":"BMC Mol. Cell. Biol."},{"key":"10.1016\/j.bbrc.2020.10.094_bib49","doi-asserted-by":"crossref","first-page":"198068","DOI":"10.1016\/j.virusres.2020.198068","article-title":"Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors","volume":"286","author":"Romeo","year":"2020","journal-title":"Virus Res."},{"key":"10.1016\/j.bbrc.2020.10.094_bib50","doi-asserted-by":"crossref","first-page":"13866","DOI":"10.1038\/s41598-020-70863-9","article-title":"An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors","volume":"10","author":"Trezza","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2020.10.094_bib51","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s11655-020-3427-6","article-title":"Silico screening of potential spike glycoprotein inhibitors of SARS-CoV-2 with drug repurposing strategy","volume":"26","author":"Wei","year":"2020","journal-title":"Chin. J. Integr. Med."},{"key":"10.1016\/j.bbrc.2020.10.094_bib52","doi-asserted-by":"crossref","first-page":"104419","DOI":"10.1016\/j.meegid.2020.104419","article-title":"Eltrombopag is a potential target for drug intervention in SARS-CoV-2 spike protein","volume":"85","author":"Feng","year":"2020","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.bbrc.2020.10.094_bib53","doi-asserted-by":"crossref","first-page":"100860","DOI":"10.1016\/j.genrep.2020.100860","article-title":"Silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors","volume":"21","author":"Gurung","year":"2020","journal-title":"Gene. Rep."},{"key":"10.1016\/j.bbrc.2020.10.094_bib54","doi-asserted-by":"crossref","first-page":"173430","DOI":"10.1016\/j.ejphar.2020.173430","article-title":"In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2","volume":"886","author":"Deshpande","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrc.2020.10.094_bib55","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/j.csbj.2020.08.016","article-title":"Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2","volume":"18","author":"Li","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.bbrc.2020.10.094_bib56","doi-asserted-by":"crossref","first-page":"105495","DOI":"10.1016\/j.ejps.2020.105495","article-title":"Structure-based drug repositioning over the human TMPRSS2 protease domain: search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages","volume":"153","author":"Singh","year":"2020","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.bbrc.2020.10.094_bib57","doi-asserted-by":"crossref","first-page":"107697","DOI":"10.1016\/j.jmgm.2020.107697","article-title":"Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: insights from a molecular mechanics-assisted structure-based virtual screening experiment","volume":"100","author":"Terali","year":"2020","journal-title":"J.\u00a0Mol. Graph. Model."},{"key":"10.1016\/j.bbrc.2020.10.094_bib58","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2020.10.094_bib59","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1038\/s41467-020-18233-x","article-title":"Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease","volume":"11","author":"Fu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.10.094_bib60","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.bbrc.2020.10.094_bib61","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3389\/fmicb.2020.01704","article-title":"Combined prophylactic and therapeutic use maximizes hydroxychloroquine anti-SARS-CoV-2 effects in\u00a0vitro","volume":"11","author":"Clementi","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.bbrc.2020.10.094_bib62","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2020.10.094_bib63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.virol.2020.05.002","article-title":"The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells","volume":"547","author":"Rothan","year":"2020","journal-title":"Virology"},{"key":"10.1016\/j.bbrc.2020.10.094_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00900-20","article-title":"Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle","volume":"64","author":"Salgado-Benvindo","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2020.10.094_bib65","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in\u00a0vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.bbrc.2020.10.094_bib66","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/v12060629","article-title":"The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in\u00a0vitro in a cell-type-dependent manner","volume":"12","author":"Yamamoto","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.bbrc.2020.10.094_bib68","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in\u00a0vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell. Discov."},{"key":"10.1016\/j.bbrc.2020.10.094_bib69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in\u00a0vitro","volume":"6","author":"Wang","year":"2020","journal-title":"Cell. Discov."},{"key":"10.1016\/j.bbrc.2020.10.094_bib70","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in\u00a0vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2020.10.094_bib71","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1021\/acsinfecdis.0c00522","article-title":"Anti-SARS-CoV-2 potential of artemisinins in\u00a0vitro","volume":"6","author":"Cao","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.bbrc.2020.10.094_bib72","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in\u00a0vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2020.10.094_bib73","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00825-20","article-title":"Atazanavir, alone or in combination with ritonavir, inhibits SARS-CoV-2 replication and proinflammatory cytokine production","volume":"64","author":"Fintelman-Rodrigues","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2020.10.094_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/v12060642","article-title":"Potential antiviral options against SARS-CoV-2 infection","volume":"12","author":"Ianevski","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.bbrc.2020.10.094_bib75","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/1348-0421.12828","article-title":"Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2","volume":"64","author":"Kato","year":"2020","journal-title":"Microbiol. Immunol."},{"key":"10.1016\/j.bbrc.2020.10.094_bib76","doi-asserted-by":"crossref","first-page":"104878","DOI":"10.1016\/j.antiviral.2020.104878","article-title":"In\u00a0vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2","volume":"181","author":"Pizzorno","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2020.10.094_bib77","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1080\/22221751.2020.1772676","article-title":"Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture","volume":"9","author":"Zhang","year":"2020","journal-title":"Emerg. Microb. Infect."},{"key":"10.1016\/j.bbrc.2020.10.094_bib78","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25985","article-title":"The anti-HIV drug nelfinavir mesylate (Viracept) is a potent inhibitor of cell fusion caused by the SARSCoV-2 spike (S) glycoprotein warranting further evaluation as an antiviral against COVID-19 infections","author":"Musarrat","year":"2020","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.bbrc.2020.10.094_bib79","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/CM9.0000000000000797","article-title":"Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model","volume":"133","author":"Fan","year":"2020","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.bbrc.2020.10.094_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00819-20","article-title":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs","volume":"64","author":"Jeon","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2020.10.094_bib81","doi-asserted-by":"crossref","first-page":"104960","DOI":"10.1016\/j.phrs.2020.104960","article-title":"Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system","volume":"159","author":"Yuan","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbrc.2020.10.094_bib82","doi-asserted-by":"crossref","first-page":"13093","DOI":"10.1038\/s41598-020-70143-6","article-title":"In\u00a0vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication","volume":"10","author":"Touret","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2020.10.094_bib83","series-title":"Multidrug Treatment with Nelfinavir and Cepharanthine against COVID-19","author":"Ohashi","year":"2020"},{"key":"10.1016\/j.bbrc.2020.10.094_bib84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"Riva","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib85","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41586-020-2575-3","article-title":"Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2","volume":"585","author":"Hoffmann","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib86","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00985-20","article-title":"Type I and type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures","volume":"94","author":"Vanderheiden","year":"2020","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.bbrc.2020.10.094_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2020.09.013","article-title":"SARS-CoV-2 infection of pluripotent stem cell-derived human lung alveolar type 2 cells elicits a rapid epithelial-intrinsic inflammatory response","author":"Huang","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib88","doi-asserted-by":"crossref","DOI":"10.1089\/scd.2020.0152","article-title":"Human induced pluripotent stem cell-derived lung epithelial system for SARS-CoV-2 infection modeling and its potential in drug repurposing","author":"Surendran","year":"2020","journal-title":"Stem Cell. Dev."},{"key":"10.1016\/j.bbrc.2020.10.094_bib89","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1126\/science.abc1669","article-title":"SARS-CoV-2 productively infects human gut enterocytes","volume":"369","author":"Lamers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.094_bib90","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.cell.2020.04.004","article-title":"Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2","volume":"181","author":"Monteil","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib91","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106230","article-title":"SARS-CoV-2 targets neurons of 3D human brain organoids","author":"Ramani","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.bbrc.2020.10.094_bib92","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2020106057","article-title":"Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol","author":"Wang","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.bbrc.2020.10.094_bib93","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.stem.2020.06.015","article-title":"A\u00a0human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids","volume":"27","author":"Yang","year":"2020","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/v12091004","article-title":"Infection of brain organoids and 2D cortical neurons with SARS-CoV-2 pseudovirus","volume":"12","author":"Yi","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.bbrc.2020.10.094_bib95","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc3582","article-title":"TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes","volume":"5","author":"Zang","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbrc.2020.10.094_bib96","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41591-020-0912-6","article-title":"Infection of bat and human intestinal organoids by SARS-CoV-2","volume":"26","author":"Zhou","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2020.10.094_bib97","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-020-2312-y","article-title":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice","volume":"583","author":"Bao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib98","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2020.06.011","article-title":"A\u00a0SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies","volume":"182","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib99","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1073\/pnas.2009799117","article-title":"Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development","volume":"117","author":"Imai","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2020.10.094_bib100","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201241","article-title":"Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling","volume":"217","author":"Israelow","year":"2020","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.bbrc.2020.10.094_bib101","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","article-title":"Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2","volume":"182","author":"Jiang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib102","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.chom.2020.03.023","article-title":"Infection and rapid transmission of SARS-CoV-2 in ferrets","volume":"27","author":"Kim","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bbrc.2020.10.094_bib103","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-020-2324-7","article-title":"Respiratory disease in rhesus macaques inoculated with SARS-CoV-2","volume":"585","author":"Munster","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib104","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1038\/s41467-020-17367-2","article-title":"SARS-CoV-2 is transmitted via contact and via the air between ferrets","volume":"11","author":"Richard","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.10.094_bib105","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1126\/science.abb7314","article-title":"Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model","volume":"368","author":"Rockx","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.094_bib106","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.094_bib107","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","article-title":"Pathogenesis and transmission of SARS-CoV-2 in golden hamsters","volume":"583","author":"Sia","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib108","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","article-title":"A\u00a0mouse model of SARS-CoV-2 infection and pathogenesis","volume":"28","author":"Sun","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.bbrc.2020.10.094_bib109","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2708-8","article-title":"A\u00a0mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures","author":"Dinnon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib110","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1126\/science.abc4730","article-title":"Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy","volume":"369","author":"Gu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.094_bib111","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A\u00a0thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib112","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib113","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","author":"Corbett","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2020.10.094_bib114","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cell.2020.08.026","article-title":"A\u00a0single-dose intranasal Chad vaccine protects upper and lower respiratory tracts against SARS-CoV-2","volume":"183","author":"Hassan","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.09.007","article-title":"High potency of a bivalent human VH domain in SARS-CoV-2 animal models","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib116","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib117","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.10.094_bib118","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1038\/s41467-020-17972-1","article-title":"A\u00a0single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge","volume":"11","author":"Wu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.10.094_bib119","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.10.094_bib120","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib121","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.10.094_bib122","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1038\/s41467-020-17907-w","article-title":"Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients","volume":"11","author":"Funnell","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.10.094_bib123","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01218-20","article-title":"Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in\u00a0vitro and SARS-CoV in\u00a0vivo","author":"Weston","year":"2020","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.bbrc.2020.10.094_bib124","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01114-20","article-title":"Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets","volume":"11","author":"Park","year":"2020","journal-title":"mBio"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20320234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20320234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:59:16Z","timestamp":1757764756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20320234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":124,"alternative-id":["S0006291X20320234"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.10.094","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in\u00a0vitro approaches","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.10.094","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}